LifeActive Transdermal Delivery Formulations Patent Application
Summary
USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.
What changed
The USPTO published a patent application (US20260090982A1) for LifeActive, Inc. disclosing transdermal delivery formulations comprising weak organic acid transdermal accelerants (pKa >2.0, pH 1.5-2.5) combined with fatty acid microemulsions containing nonionic emulsifiers, water, and cis-unsaturated long-chain fatty acids (C12-C26). The formulations create micelles and liposomes encapsulating therapeutic compounds and are designed for optimal solubility and absorption in high humidity conditions such as showers or saunas. The application covers human and veterinary therapeutics, agricultural applications, and spans numerous CPC classifications including various pharmaceutical compounds, vitamins, and nutrients.
Patent applicants and those developing transdermal delivery technologies should review the disclosed formulation methodology, which may affect freedom-to-operate assessments for competing formulations. The application is currently in draft stage and subject to USPTO examination. No compliance deadlines or regulatory penalties apply to this patent publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRANSDERMAL DELIVERY FORMULATIONS
Application US20260090982A1 Kind: A1 Apr 02, 2026
Assignee
LifeActive, Inc.
Inventors
Calvin Dexter MORRIS, Burgess A. THOMASSON, JR., Scott A. JENKINS
Abstract
Provided are transdermal delivery formulations, and methods for the manufacture thereof, for the epicutaneous administration of therapeutic agents, drugs, and nutrients to human subjects; veterinary animals; domesticated or undomesticated animals, plants or insects; or agricultural animals, plants, or insects. Transdermal delivery formulations disclosed herein comprise a homogenous mixture of (a) a transdermal accelerant comprising a weak organic acid having a pKa greater than 2.0 and (b) a microemulsion comprising a nonionic emulsifier, water, and a cis-unsaturated long-chain fatty acid. Fatty acid microemulsions are combined with the acidified transdermal accelerants having a pH greater than 1.0 (typically from 1.5 to 2.5) to yield a homogenous transdermal delivery formulation comprising fatty acid micelles and/or liposomes that encapsulate one or more compound, such as a nutrient or a drug, and incorporate one or more cis-unsaturated fatty acid having a 12 to 26 carbon chain that includes one or more double bond in a cis configuration. Transdermal delivery formulations exhibit ideal solubility and absorption properties in high humidity conditions, such as in a warm to hot shower or sauna.
CPC Classifications
A61K 9/0014 A61K 9/1075 A61K 31/047 A61K 31/05 A61K 31/07 A61K 31/121 A61K 31/155 A61K 31/192 A61K 31/198 A61K 31/205 A61K 31/355 A61K 31/375 A61K 31/401 A61K 31/4045 A61K 31/405 A61K 31/4172 A61K 31/4188 A61K 31/455 A61K 31/51 A61K 31/525 A61K 31/593 A61K 31/714 A61K 35/60 A61K 36/21 A61K 36/9066 A61K 38/063 A61K 45/06 A61K 47/12 A61K 47/24 A61K 47/44 A61P 25/28
Filing Date
2025-12-05
Application No.
19411130
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.